Alvotech and teva announce acceptance of u.s. biologics license application for avt04, a proposed biosimilar to stelara® (ustekinumab)

Reykjavik, iceland & parsippany, n.j.--( business wire )--alvotech (nasdaq: alvo), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and teva pharmaceuticals, a u.s. affiliate of teva pharmaceutical industries ltd. (nyse and tase: teva), today announced that the u.s. food and drug administration (fda) has accepted for review a biologics license application (bla) for avt04, alvotech's proposed biosimilar to stelara® (ustekinumab), which is prescribed to treat a variety of inflammatory conditions. the companies anticipate that the fda's review will be completed in second half of 2023.
ALVO Ratings Summary
ALVO Quant Ranking